Signing a plea agreement that bans hims from the grounds of the University of Virginia and makes him pay court costs, the ...

Heart disease is a type of cardiovascular disease that affects the heart’s structure and function. Several different heart ...

I make the case that investors are not paying up for any GLP1 prospects, or even, for that matter, the actual core business that Hims & Hers (NYSE:HIMS) operates in. I argue that there's a lot ...

Hims & Hers (NYSE:HIMS), the telehealth platform that offers compounded versions of weight loss drugs, dropped more than 10% on Thursday after the FDA confirmed that Eli Lilly's (LLY) GLP-1 ...

Shares of Hims & Hers Health fell almost 10% today following an announcement from the U.S. Food and Drug Administration (FDA) that competitor Eli Lilly’s obesity and diabetes drugs are no longer ...

In contrast, shares of competitor Hims & Hers Health (HIMS) are plummeting following this news. Market Domination hosts Madison Mills and Josh Schafer discuss the news and Citi's take on it.

We came across a bullish thesis on Hims & Hers Health, Inc. (HIMS) on La Newsletter de Momentum’s Substack by Mexican Investor. In this article, we will summarize the bulls’ thesis on HIMS.

Bloomberg / Contributor / Getty Images Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration (FDA) said Eli Lilly's popular weight-loss drugs are no longer on its list ...

Hims & Hers Health Q3 2024 revenue projected to surpass estimates by $5M-$10M. Truist consumer survey shows 10% use compounded GLP-1 medications, while 14% prefer branded options. Thursday, The ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our P/B Growth Investor model based on the published ...

Compounded semaglutide is semaglutide with an altered formula to create an unbranded alternative to Wegovy and Ozempic.